The 9 references in paper S. Oranskiy P., L. Eliseeva N., С. Оранский П., Л. Елисеева Н. (2010) “ПРОФИЛЬ БЕЗОПАСНОСТИ ТЕРАПИИ ЭРИТРОПОЭЗСТИМУЛИРУЮЩИМИ АГЕНТАМИ ПРИ РЕНАЛЬНОЙ АНЕМИИ В ДОДИАЛИЗНОМ ПЕРИОДЕ: ЗНАЧЕНИЕ ИССЛЕДОВАНИЯ TREAT // THE SAFETY PROFILE OF THERAPY ERITHROPOIESIS STIMULATING AGENTS IN RENAL ANEMIA IN THE PREDIALYSIS PERIOD: THE IMPORTANCE OF TREAT STUDY” / spz:neicon:nefr:y:2010:i:4:p:23-26

1
KDOQI Clinical PracticeGuidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S1-S146
(check this in PDF content)
2
2. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: ii1- ii47
(check this in PDF content)
3
Российские национальные рекомендации по диаг­ ностике и лечению анемии при хронической болезни почек. Анемия 2006 (3): 3-19
(check this in PDF content)
4
Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098
(check this in PDF content)
5
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471­ 530
(check this in PDF content)
6
Zoccali C, Abramowicz D, Cannata-Andia JB et al. European Best Practice Guidelines; European renal best practice. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166
(check this in PDF content)
7
Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006; 335: 2071-2084
(check this in PDF content)
8
Pfeffer MA, Burdmann EA, Chen CYet al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
(check this in PDF content)
9
Locatelli F, Aljama P, Canaud B. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
(check this in PDF content)